An interventional study of Use of a decision support system on the EV1000 monitoring (AFM mode) and Manual application of the GDFT protocol (standard of care) in Monitoring, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-08-30.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other
This study will compare a group of patients managed with a manual GDFT protocol (using the EV1000 monitoring device; Edwards Life sciences, Irvine, USA) to a group of patients managed using a novel real time clinical decision support system for goal directed fluid therapy (GDFT) guidance on microvascular parameters in patients undergoing major abdominal or orthopedic surgery.
Many trials have indicated that GDFT strategies may benefit high-risk surgical patients but these strategies are infrequently implemented on a day to day basis. It has also been shown that without any goal or protocol for fluid resuscitation, large inter- and intra-provider variability exist and have been correlated with marked variations in patient outcomes. Even under ideal study conditions, strict adherence to GDFT protocols is hampered by the workload and concentration required for consistent implementation.Haemodynamic monitors and protocols alone do not enable optimal fluid titration to be provided consistently to all patients - there must also be appropriate and timely interpretation and intervention.
To address this problem of consistency and protocol adherence, a novel real time clinical decision support system, "Assisted Fluid Management" (AFM), has been designed to help ease some of the workload associated with GDFT protocol implementation. The AFM system (released on the European market in March 2017) may help increase GDFT protocol adherence while leaving direction and guidance in the hands of the care providers. This system can suggest fluid bolus administration, analyse the effects of the bolus, and continually re-assess the patient for further fluid requirements.
Mean arterial pressure will be at least maintained in both groups above 65 mmHg with norepinephrine administration. Vasopressors administration is standardised in both groups (objective is a MAP of > 65 mmHg) and the only difference will be the way fluid boluses are given to the patient (following standard of care (manual protocol) of following the assisted fluid management recommandations)
A recent published study demonstrated that the implementation of the AFM for GDFT guidance resulted in a significantly longer period during surgery in a preload independent state (defined as a SVV \< 13%) with a reduced total amount of fluid administered without any difference in postoperative complications.
Another recent study demonstrated that during abdominal surgery, microvascular perfusion is impaired during preload dependence (SVV >13%) and recovers after fluid administration (preload independent state)
Therefore the goal of this bicentric randomized controlled trial is to compare a manual GDFT approach (standard of care actually in the department) versus an Assisted fluid management approach (using the AFM mode) on the Microvascular flow index.
We assume that this novel clinical decision support system will allow patients to have less alterations of their microvascular parameters than patients managed under standard of care (GDFT but without the assisted fluid management mode)
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,578 studies on the registry; 1,030 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This group of patients will receive fluid administration during surgery based on a manual GDFT protocol actually in place in the department using the EV1000 monitoring device (Edwards Life sciences, Irvine, USA)
Other: Manual application of the GDFT protocol (standard of care)
This group of patients will receive fluid administration during surgery based on a novel clinical decision support system for GDFT guidance using the EV1000 monitoring device (Edwards Life sciences, Irvine, USA)
Device: Use of a decision support system on the EV1000 monitoring (AFM mode)
The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical decision support system for fluid administration called AFM (assisted fluid management) Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
Manual application of a GDFT protocol to guide fluid administration. Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
Microvascular flow index
Comparison of this index between groups during the intraoperative period. The image is divided into four quadrants and the predominant type of flow in very small vessels is assessed in each quadrant using an ordinal score (0= no flow; 1 = intermittent flow; 2 = sluggish flow; 3 = normal flow). The overall score, called microvascular flow index, is the sum of each quadrant score divided by the number of quadrants
Time frame: Day 0
Composite criteria of minor postoperative complications
This composite score includes 8 items (1 point for each item present; minimum score is 0 and maximum is 8 points) 1. postoperative nausea and vomiting 2. delirium and confusion 3. Infection of surgical site 4. urinary infection 5. acute kidney injury (KDIGO I \& II classiciation) 6. paralytic ileus 7. other infection (skin, catheter, unknown etc) 8. Readmission to the hospital within 30 days postoperative
Time frame: 30 days postsurgery
Composite criteria of major postoperative complications
This composite score includes 14 items (one point for each item present; minimum score is 0 and maximum is 14 points): 1. stoma dehiscence 2. Peritonitis 3. Sepsis 4. wound dehiscence 5. bleeding requiring a redo surgery 6. pulmonary embolism 7. pulmonary edema 8. Pneumonia 9. acute coronary syndrome 10. atrial fibrillation 11. stroke 12. Dialysis 13. non scheduled redo surgery 14. 30days mortality (all causes)
Time frame: 30 days postsurgery
Stroke volume over the procedure
average stroke volume over the procedure
Time frame: Postoperative day 1
Cardiac output over the procedure
average cardiac output over the surgery
Time frame: Postoperative day 1
Total Fluid received during the procedure
amount of fluid received during surgery
Time frame: Postoperative day 1
Net fluid balance
Net fluid balance at the end of the surgery
Time frame: Postoperative day 1
Hospital length of stay
hospital length of stay
Time frame: 30 days postsurgery
Proportion of perfused vessels
Comparison of this index between groups during the intraoperative period. This is calculated as follow: 100 x (total number of vessels - \[no flow+intermittent flow\]/total number of vessels.
Time frame: Day 0
Perfused vessel density
Comparison of this index between groups during the intraoperative period. This is calculated automatically by dividing the area of perfused vessels by the total area of interest using the Automated Vascular Analysis software.
Time frame: Day 0
Heterogeneity index
Comparison of this index between groups during the intraoperative period. This is calculated as follows: (highest site microvascular flow index-lowest site microvascular flow index) divided by the mean of the microvascular flow index of all sublingual sites.
Time frame: Day 0
minimal value of microvascular flow index
minimal value of this index during the intraoperative period
Time frame: Day 0
Plan to share: No
Ran from Dec 2021 to primary completion in Jul 2022, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →